{{Refimprove|date=August 2013}}

{{Drugbox
| verifiedrevid = 458972860
| IUPAC_name = (2''S'',5''R'',6''R'')-3,3-dimethyl-7-oxo-6-<nowiki/>{[(2''R'')-2-<nowiki/>{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| image = Azlocillin skeletal.svg
<!-- Clinical data -->
| tradename =
| Drugs.com = {{drugs.com|international|azlocillin}}
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 37091-66-0
| ATC_prefix = J01
| ATC_suffix = CA09
| PubChem = 6479523
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01061
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4980416
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = HUM6H389W0
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02339
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2956
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1537
<!-- Chemical data -->
| C=20 | H=23 | N=5 | O=6 | S=1
| molecular_weight = 461.491 g/mol
| smiles = O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)NC(=O)N2C(=O)NCC2)[C@H]4SC3(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JTWOMNBEOCYFNV-NFFDBFGFSA-N
}}

'''Azlocillin''' is an [[acyl]][[ampicillin]] [[antibiotic]] with an extended spectrum of activity and greater ''[[in vitro]]'' potency than the carboxy [[penicillin]]s.
Azlocillin is similar to [[mezlocillin]] and [[piperacillin]]. It demonstrates antibacterial activity against a broad spectrum of [[bacteria]], including ''[[Pseudomonas aeruginosa]]'' and, in contrast to most [[cephalosporin]]s, exhibits activity against [[enterococcus|enterococci]].

== Spectrum of bacterial susceptibility ==
Azlocillin is considered a broad spectrum antibiotic and can be used against a number of Gram positive and Gram negative bacteria. The following represents MIC susceptibility data for a few medically significant organisms.<ref>http://www.toku-e.com/Assets/MIC/Azlocillin%20sodium%20salt.pdf</ref>
* ''Escherichia coli'' 1 μg/mL – 32 μg/mL
* ''Haemophilus'' spp. 0.03 μg/mL – 2 μg/mL
* ''Pseudomonas aeruginosa'' 4 μg/mL – 6.25 μg/mL
== Synthesis ==
[[File:Azlocillin synthesis.svg|thumb|left|600px|Azlocillin synthesis: {{cite patent|FR|2100682}} eidem {{US patent|3933795}} <ref name=Konig>H. B. Konig et al., Eur. J. Med. Chem. - Chim. Ther. 17, 59 (1982).</ref>]]
[[File:Azlocillin synthesis2.svg|thumb|left|450px|Azlocillin synthesis 2:<ref name=Konig /><ref>{{cite journal|doi=10.1021/jm00324a056|pmid=4291383|title=Octamethylbiguanide Perchlorate|journal=Journal of Medicinal Chemistry|volume=9|issue=6|pages=980|year=1966|last1=Bauer|first1=Victor J.|last2=Safir|first2=S. R.}}</ref>]]
An interesting alternative synthesis of azlocillin involves activation of the substituted phenylglycine analogue '''1''' with 1,3-dimethyl-2-chloro-1-imidazolinium chloride ('''2''') and then condensation with [[6-APA]].

== See also ==
*[[Methicillin]]
== References ==
{{reflist|30em}}

{{PenicillinAntiBiotics}}

[[Category:Penicillins]]
[[Category:Enantiopure drugs]]
[[Category:Imidazolidinones]]


{{Antibiotic-stub}}